Feinstein Institute for Medical Research

From shadowing to Lego Night, careers start in school

By ROSALIE DRAGO // One of the most important business relationships an employer can invest in is the school-business partnership. Urgency in filling immediate and near-term jobs is an obvious priority. Advancing career awareness and skills development among the emerging workforce – those just entering the pipeline for future hiring – is just as critical. In junior year of high school, we ask students what they think they might want to do for a living….


No. 380: On Coach K, ‘foodpreneurs’ and Donna Drake’s new digs – plus, introducing our 2019 Innovators of the Year!

  Middle march: Onwards and upwards, dear readers, as this latest week of socioeconomic progress plows ahead. It’s Feb. 13 out there, and if you had boozing brawler Guo Wei leading a military coup and declaring himself emperor of China’s short-lived Later Zhou dynasty on this date in 951 A.D., nice work – here’s a voucher for 100 copper Ban Liang coins. Dial it up: Before we dive in, a peaceful World Radio Day –…


No 379: Tuning in at Hofstra, soaring high at JFK and music by John Williams (plus: a new origin story for the universe)

  Finishing touch: And down the stretch we come, dear readers, with the end of another busy workweek and the promised land of another well-earned weekend coming up fast. It’s Friday out there, Feb. 8 to be precise, and good luck to all our readers in India preparing to pop the question on this romantic Propose Day 2019. The pickings are slim (Scout’s honor): Here in the States, it’s National Opera Day (just two years…


Tracey, global team unearth new bioelectronic clue

By GREGORY ZELLER // An international research team featuring one of Long Island’s great innovators has uncovered a potential key to fighting viral infections – a bioelectronic-medicine breakthrough with wide-ranging implications for a multitude of patients and conditions. Feinstein Institute for Medical Research President and CEO Kevin Tracey, a global electronic nerve-stimulation and bioelectronic medicine pioneer, joined with scientists from Canada, Europe and Asia to research and announce the new findings, detailed in an article…


No. 376: The mahatma, the pharmacist, and life in the home of the economically influential immigrant

  Middle class: It’s the third day of the week – fourth if you’re a Quaker – and whether you dig “Woden” or “Odin,” welcome to Wednesday, dear readers, and the midpoint of another exciting run of socioeconomic innovation. It’s Jan. 30 out there, and before we dive in, welcome new newsletter subscribers Hannah, Jessica, Kenneth, Liu, Vivian, Tom, Edmon, Micki, Scott, Deanette, Justin and Raj. Goodness, they’re piling up fast these days! Enjoy the…


Top psychologist to lead new behavioral-health center

By GREGORY ZELLER // A highly credentialed expert in the psychological and social risk factors influencing cardiovascular disease will head the Feinstein Institute for Medical Research’s new behavioral-health center. Karina Davidson, most recently a vice-dean at Columbia University and chief academic officer of New York Presbyterian Hospital, will lead the Manhattan-based center, which will explore how behavior affects management of chronic cardiovascular diseases. Linking behavioral and cardiovascular health is second nature to Davidson, whose research…


No: 365: Electrons, hackathons, gadget gifts and yes, America, there is a climate change

  Golden mettle: Congratulations, dear reader – you’ve reached the 50th Friday of 2018 (go ahead and count, if you don’t believe us) and the end of another busy week of socioeconomic innovation. You are to be commended. It’s Dec. 14 out there, and we have plenty of interesting days to choose from – it’s international Monkey Day and, here in the USA, National Salesperson Day. Because it just sounds so badass: But we’re going…


No. 364: Planning HQ2, digitizing Robert Moses and still taking giant leaps for mankind, a half-century later

  All downhill from here: Over the hump we go, dear readers, as another wintry Wednesday arrives (though it’s still not winter) and we race through the midpoint of another busy workweek. Ride share: Before we get to it, welcome new newsletter subscribers Alida, Greg, Michael, Marc, Carmela, George, Nina, Stanley, Stacy, Brittany, Sarah, Christopher, MJ and Cristian. What a fine-looking group! Please keep your hands in the car at all times. Not taking sides:…


NIH gets behind new Feinstein Institute sepsis study

By GREGORY ZELLER // A five-year National Institutes of Health grant will pack the protein into a new Long Island sepsis study. Monowar Aziz, an assistant professor at the Manhasset-based Feinstein Institute for Medical Research, will apply the $1.68 million award to his work examining protein’s role in inflammation and injury in due to sepsis, a body-wide immune system reaction to infection. Sepsis is a sinister opponent, causing nearly half-a-million U.S. deaths annually and leaving…


No. 361: Meteors! Mark Twain! Carter DeLuca relocates! And some very fine fellows lead LI’s labs

  The month that wouldn’t die: It’s eight days since Thanksgiving and still November, dear readers, a calendar quirk that makes this Nov. 30, and Friday, and the end of another busy week of socioeconomic innovation. It’s also the 531st anniversary of Reinheitsgebot, the German beer-purity law requiring that beer be brewed from only water, malt and hops. Please commemorate responsibly. Route canal: In other water-related Nov. 30 news, ground was broken today (in 1824)…


On the right path in Feinstein Parkinson’s pursuit

By GREGORY ZELLER // A new gene therapy can literally rewire the brains of Parkinson’s disease patients – and may rewrite the book on treatment of the nation’s second most-common neurodegenerative disease. A team of scientists from the Manhasset-based Feinstein Institute for Medical Research has published findings indicating that AAV2-GAD, an emerging Parkinson’s gene therapy, creates new circuits in the brain promoting improved motor skills – setting up AAV2-GAD for a critical final found of…


No. 358: Softheon speeding, Central Islip redeveloping and Vision Long Island seeing things a little differently

  Done deal: You’ve made it, dear reader – it’s Friday, Nov. 16, another week of socioeconomic progress is in the books and another weekend (followed by a blessedly short holiday week) lies ahead. Make a day of it: To our Icelandic readers, happy Dagur íslenskrar tungu. To all members of the United Nations, remember to observe the International Day for Tolerance. It’s also National Fast Food Day. Only in America. Live at five: Now…


NIH to Feinstein: Stick out that chest (bioelectrically)

By GREGORY ZELLER // With new treatments for obesity, heart failure and a host of other conditions in sight, a Feinstein Institute researcher will zero in on specific abdominal targets in a new “precision bioelectronic medicine” study. North Shore University Hospital and Long Island Jewish Medical Center Chief of Gastroenterology Larry Miller, who also directs the Gastroenterology Laboratory at the Feinstein Institute for Medical Research, has received a $1.4 million National Institutes of Health grant…


Feinstein researchers eye chronic post-storm despair

By GREGORY ZELLER // A team of Feinstein Institute for Medical Research investigators is digging deep into the mental toll natural disasters take on survivors. The team – led by Rebecca Schwartz, an associate investigator at the Manhasset-based Feinstein Institute, R&D division of the Northwell Health system – presented its findings during a roundtable discussion at the American Public Health Association’s annual meeting, held this week in California. According to the research, exposure to natural…


Researchers eye genetic factors in schizophrenia drugs

By GREGORY ZELLER // A new study by Feinstein Institute for Medical Research scientists suggests that a patient’s response to antipsychotic pharmaceuticals can be predicted by genetic predispositions. Schizophrenia – characterized by delusions, hallucinations and disorganized thoughts – is one of the leading causes of disability in the United States. Antipsychotic pharmaceuticals are a common treatment option, but such therapies are often “given without guidance from lab tests to show effectiveness, as is common in…